Study details
Enrolling now
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Bluefin Biomedicine, Inc.
NCT IDNCT07287644ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2/3
Target enrollment
210
Study length
about 1.7 years
Ages
18–75
Locations
31 sites in AZ, CA, FL +15
About this study
Researchers are testing whether BFB759, a biological treatment, is effective and safe compared to a placebo for people with moderate to severe hidradenitis suppurativa. The trial will last approximately 36 to 40 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo for BFB759
- 2.Receive BFB759
PhasePhase 2/Phase 3
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Evaluate the safety/tolerability of BFB759, To evaluate the clinical activity of BFB759 using the Skin Pain Numerical Rating Scale (NRS)